Kelly Moynihan, PhD

Kelly is a VP at Curie.Bio where she works alongside founders to advance the development of innovative therapeutics companies. She has a mix of operational and investing experience. Previously, at Third Rock Ventures, Kelly was involved in the formation and launch of multiple companies in the immunology space, including Celsius Therapeutics, Abata Therapeutics, and Asher Biotherapeutics. After the launch of Asher, she joined full time and operated for 4 years as Program Team Lead for AB248, the first CD8 cis-targeted IL-2 to enter clinical development, leading the project from initiation through 18 months of clinical development. Her scientific background is in immunology, and she holds a Ph.D. from MIT, where she trained with Darrell Irvine and Dane Wittrup.